The technology platform based on recombinant proteins has been successfully used for many years to produce vaccines and other pharmaceutical products against a wide range of different diseases. To date, clinical trials are carried out around the world for more than 1,000 different medicinal products, including recombinant ones.
The recombinant N protein of the SARS-CoV-2 virus is obtained using Escherichia coli, one of the most studied microorganisms in science. It is used to obtain thousands of different safe and effective proteins daily for various applications.
